Molecular Cytogenetics Market

Global Molecular Cytogenetics Market Size (2024 to 2029)

The global molecular cytogenetics market size is forecasted to grow to USD 4199.73 Million by 2029 from USD 2549.24 Million in 2024, registering a CAGR of 10.5% from 2024 to 2029. 

Molecular biology and cytogenetics are the two primary fields studied under molecular cytogenetics. In addition, the study of chromosomes is termed cytogenetics. Molecular cytogenetics further delves into the analysis of genetic variations and alterations through in-situ hybridization techniques.

MARKET DRIVERS

The growing incidence of congenital & genetic disorders and subsequent rise in early disease diagnostics propel the global molecular cytogenetics market growth.

These highly advanced, high-throughput tools help identify therapeutic targets. For instance, oncogenes are implicated in tumorigenesis, besides determining the presence of chromosomal aberrations for diagnosing genetic diseases. According to the National Human Genome Research Institute (NHGRI), an estimated 350 million people worldwide live with rare diseases, of which 80% are genetic. In addition, the rise in the aging population and the growing incidence of chronic diseases are promoting the growth rate of the molecular cytogenetics market. The World Health Organization (WHO) says one in every six people is expected to be more than 60 years by 2030. Moreover, due to the increase in cancer cases, the adoption of various molecular cytogenetics techniques for diagnostic purposes increased rapidly, propelling the market’s growth rate. Growing penetration for molecular cytogenetics in clinical pathological testing and the rise in focus on targeted cancer treatment are other factors driving the molecular cytogenetics market.

In addition, the emergence of rapid testing platforms for the characterization of chromosomal aberrations with very high precision, conjoined with the development of highly sensitive diagnostic tools propel the market's growth rate. Genetic disorders claim over 3000 infant lives per year, per the data published by the Centres for Disease Control and Prevention (CDC). Therefore, molecular diagnostic techniques such as FISH and CGH are expected to witness high penetration because of high mortality rates. In addition, next-generation sequencing (NGS) technology, which enables comprehensive and cost-effective analyses, is another factor contributing to the growth of this market.

Furthermore, the rise in technological advancements in molecular cytogenetics tools is estimated to fuel the market’s growth rate during the forecast period. For instance, new techniques like FISH and Comparative Genomic Hybridization (CGH) provide out-and-out information about cancer-related molecular signatures. In addition, next-generation sequencing technology, which enables comprehensive and cost-effective analyses, contributes to this market's growth. Moreover, the increase in pharmacogenomic activities and the rise in government investments for better treatment propel market growth. In addition, the rise in the adoption of molecular cytogenetics testing in emerging nations promotes the market’s growth rate. The increasing number of cancer cases in Asian countries is estimated to fuel the molecular cytogenetics market in the coming years.

MARKET RESTRAINTS

The high cost associated with molecular cytogenetics testing is the major restrain for the market during the forecast period. For instance, the price of the tests starts from US$ 300 to US$ 3,000 per test, which is considerably high. Moreover, the lack of experienced workers and regulatory frameworks further hinders the growth of the molecular cytogenetics market. In addition, the lack of predictable coverage and reimbursement policies for new genomic tools is challenging the market growth. Moreover, expensive instruments and the high maintenance cost associated with the advanced techniques hinder the market. Therefore, these factors will challenge the molecular cytogenetics market in the forthcoming years.

COVID-19 Impact on the global molecular cytogenetics market

COVID-19 is a contagious disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). COVID-19 was announced as a pandemic by World Health Organisation (WHO) in March 2020. Almost all industries have been affected negatively during the lockdown, so the global economy was impacted adversely during the pandemic. The molecular cytogenetics market is not an exception. The market has endured some rough times during the pandemic and has seen a slump in the market’s growth rate. Due to the lockdown, the factories were shut down, and transportation was stopped, which disturbed the supply chain. Moreover, technological advancements were paused due to a lack of funds during the pandemic, and the key market players are putting their best foot forward for a quick market recovery. However, considering the declining Impact of COVID-19 and the growing adoption of new normalization are anticipated to aid the recovery in the molecular cytogenetics market and register a healthy CAGR during the forecast period.

REPORT COVERAGE

SEGMENTAL ANALYSIS

Global Molecular Cytogenetics Market Analysis By Product

Based on the product, the kits and reagents segment is anticipated to hold the largest global molecular cytogenetics market share during the forecast period. Factors such as the benefits associated with the segment, such as time-saving. In addition, pharmaceutical companies' growing emphasis on finding effective cancer treatments favors the segment’s growth rate. Furthermore, the rise in the demand levels from the untapped regions is further fuelling segmental growth.

Global Molecular Cytogenetics Market Analysis By Technique

Based on the technique, the CGH technology segment occupied an estimated 53% of the global market share in 2023 and is estimated to retain its leading position during the forecast period. In addition, the rising number of applications for detecting complex chromosomal arrangements using multicolor FISH techniques and SNP-array analysis is another contributing factor to the growth of this segment.

Global Molecular Cytogenetics Market Analysis By Application

Based on application, the cancer segment was the leading segment in the global molecular cytogenetics market in 2023, accounting for over 42% of the overall market.

Global Molecular Cytogenetics Market Analysis By End User

Based on end-users, the clinical and research laboratories segment captured the most significant global market share during the forecast period. The rising usage of molecular cytogenetic techniques such as FISH and CGH among the clinical and research laboratories is one of the major factors propelling the segment's growth rate.

REGIONAL ANALYSIS

Geographically, the molecular cytogenetics market in North America accounted for the largest share of the global market in 2023. The region’s dominance is likely to continue during the forecast period due to the rise in the number of genetic disorders and the, better healthcare infrastructure, and high awareness among people. The U.S. market led the market in 2021, followed by Canada. During the forecast period, the U.S. market is anticipated to hold a significant share of the North American region owing to the growing patient volume diagnosed with cancer. For instance, as per the American Cancer Society, approximately 1,762,450 new cancer cases were diagnosed, and more than 606,880 cancer deaths were only in the U.S. in 2019. Moreover, the implementation of advanced molecular cytogenetic techniques, such as FISH and array-comparative genomic hybridization (array-CGH), for early and appropriate detection of diseases and reducing the mortality rate and the severe consequences associated with genetic disorders. On the other hand, the Canadian market is expected to register a healthy CAGR during the forecast period and is expected to hold a considerable share of the North American market.

The European molecular cytogenetics market had the second-largest global market share in 2023. During the forecast period, the European region is expected to have a promising global market share. The UK, one of the noteworthy regional markets across Europe, is anticipated to showcase a noteworthy CAGR during the forecast period. Social organizations such as Leukemia & Lymphoma Society's funding to develop novel techniques used in cancer diagnosis drive the regional market growth. According to World Health Organization (WHO), cancer is the second most important cause of death in Europe, with 3.7 million new cases and 1.9 million deaths yearly. The German market is another promising regional market in Europe to watch out for and is predicted to showcase a healthy CAGR during the forecast period.

The APAC molecular cytogenetics market is predicted to witness the highest CAGR among all regions in the global market during the forecast period.

The molecular cytogenetics market in Latin America is anticipated to showcase a steady CAGR in the coming years.

The MEA molecular cytogenetics market is expected to register a moderate share in the global market during the forecast period.

KEY MARKET PARTICIPANTS

Companies dominating the global molecular cytogenetics market profiled in this report are Affymetrix, Inc., Agilent Technologies, Inc., Illumina, Inc., Abbott Laboratories, Bio-Rad Laboratories, Inc., Applied Spectral Imaging, Inc., and Thermo Fisher Scientific (Life Technologies), Inc.

RECENT MARKET DEVELOPMENTS

• Applied Spectral Imaging (ASI) and KromaTiD, Inc. announced a strategic commercial partnership in April 2021, with ASI distributing KromaTiD's proprietary Pinpoint FISHTM (PPF) probes and test services globally. Researchers worldwide utilize PPF to look for tiny and unique genetic targets in tissues, microarrays, and dissociated cells.
• In July 2021, Thermo Fisher Scientific, a global leader in science service, will promote and distribute Thermo Scientific MAS Quality Controls and LabLink xL Quality Assurance Software to use VITROS analyzers through a partnership with Ortho Clinical Diagnostics.
• PPD, Inc., a contract research organization, was acquired by Thermo Fisher in April 2021 for a total cash purchase price of $17.4 billion, including the assumption of about $3.5 billion in net debt. In fiscal 2020, PPD generated $4.7 billion in revenue, valuing the company at around $20.9 billion.
• Aug-2020, BioTek Instruments, a global pioneer in designing, manufacturing, and distributing revolutionary life science instrumentation, has been acquired by Agilent Technologies Inc.
• January of 2021, Thermo Fisher Scientific has created a new medium for creating and multiplying human T lymphocytes for cell therapy developers employing allogeneic processes (T-cells). For allogeneic cell production, Gibco CTS OpTmizer Pro Serum-Free Media (SFM) is a first-of-its-kind media solution that targets the metabolism of healthy donor cells.
• Agilent Technologies Inc. announced the expansion plans of a cutting-edge manufacturing plant in Frederick, Colorado, which develops and manufactures "oligos," tiny DNA and RNA molecules used to create nucleic acid-based medicines.

This research report on the global molecular cytogenetics market has been segmented and sub-segmented based on the product, technique, application, end-user, and region.

By Product

• Kits & Reagents
  • Testing Kits
  • Probes
  • Fluorescent Affinity Reagents
  • Other Kits & Reagents
• Instruments
• Consumables
• Software & Services

By Technique

• Comparative Genomic Hybridization
  • Array-Based Comparative Genomic Hybridization
  • Standard Comparative Genomic Hybridization
• Fluorescence in Situ Hybridization
• In Situ Hybridization
• Others

By Application

• Genetic Disorders
• Cancer
• Personalized Medicine
• Other Applications

By End User

• Clinical & Research Laboratories
• Academic Research Institutes
• Pharmaceutical & Biotechnology Companies
• Others

By End User

• Clinical & Research Laboratories
• Academic Research Institutes
• Pharmaceutical & Biotechnology Companies
• Others

By Region

• North America
• Europe
• Asia-Pacific
• Latin America
• Middle East and Africa